Merck announced on November 25, 2024, that its drug, Winrevair, significantly reduced the risk of death in patients with pulmonary arterial hypertension (PAH), a rare condition causing high blood pressure in the lungs.
The positive results came from the Phase 3 ZENITH study, which evaluated Winrevair in adults with PAH functional class III or IV at high risk of mortality. The study met its primary endpoint of time to first morbidity or mortality event.
Winrevair demonstrated a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo, on top of background PAH therapy. This strong efficacy data, months after its U.S. approval, reinforces its potential as a key growth driver for Merck.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.